At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 141 enrolled
Drug / intervention
Ramucirumab (IMC-1121B) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
In Brief
A Phase 2 clinical trial evaluating Ramucirumab (IMC-1121B) and Eribulin for Breast Cancer. Completed, enrolled 141 participants across 52 sites.
Detailed Summary
This is a study to compare the antitumor activity of ramucirumab (IMC-1121B) and eribulin together versus eribulin alone, in participants with locally recurrent or metastatic breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 2011
Enrollment StartNov 2011
Primary CompletionSep 2013
Study CompletionJun 2014
TodayJul 2026
First PostedSep 2, 2011
Enrollment StartNov 1, 2011
Primary CompletionSep 1, 2013
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.8 years ago
Interventions
Ramucirumab (IMC-1121B)biological
Administered intravenously
Eribulindrug
Administered intravenously